Egrifta (Tesamorelin) Monitoring Schedule: Labs & Exams

How Tesamorelin Works: Mechanism of Action

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) that binds pituitary GHRH receptors and triggers pulsatile release of endogenous growth hormone (GH). That pulsatile pattern matters. Continuous GH administration suppresses its own receptor sensitivity, but tesamorelin preserves the physiologic on-off rhythm that the hypothalamus normally generates [1]. GH then acts on hepatocytes to produce insulin-like growth factor 1 (IGF-1), which mediates lipolysis in visceral adipocytes.

In the phase III trial by Falutz et al. (N=412), tesamorelin 2 mg daily reduced trunk fat by approximately 15% at 26 weeks compared to placebo, as measured by CT cross-sectional area at the L4-L5 vertebral level [1]. A subsequent 52-week extension confirmed that visceral adipose tissue (VAT) reductions were maintained only with continued treatment; patients re-randomized to placebo regained fat within 26 weeks [2]. This rebound pattern is why ongoing monitoring rather than a fixed-duration protocol defines tesamorelin management.

The mechanism also explains why IGF-1 tracking is non-negotiable. Because tesamorelin amplifies the entire GH-IGF-1 axis, supraphysiologic IGF-1 levels can develop. The FDA label for Egrifta SV states: "IGF-1 levels should be monitored and tesamorelin discontinued if IGF-1 levels are persistently above the age-adjusted upper limit of normal" [3]. Dr. Julian Falutz of McGill University has noted that "the therapeutic window of GHRH analogs requires balancing fat reduction against the metabolic consequences of excess IGF-1 stimulation" [1].

Baseline Labs and Exams Before Starting Therapy

Before the first injection, a complete baseline workup establishes reference values that every subsequent lab draw will be measured against. Skip any of these, and you lose the ability to detect clinically meaningful trends.

Required baseline labs:

• Serum IGF-1 with age-adjusted reference range. The Endocrine Society recommends using the same assay laboratory throughout treatment to avoid inter-assay variability [4].
• Fasting glucose and HbA1c. Tesamorelin can impair glucose tolerance through GH-mediated insulin antagonism. In the key trials, new-onset diabetes occurred in 3.3% of tesamorelin-treated patients versus 1.7% on placebo [3].
• Fasting lipid panel. Tesamorelin modestly improved triglycerides in trial populations (reduction of approximately 50 mg/dL vs. placebo at 26 weeks), but individual responses vary [2].
• Hepatic function panel. Post-marketing data and a 2015 secondary analysis showed tesamorelin reduced liver fat fraction in patients with HIV-associated NAFLD, making ALT and AST useful tracking markers [5].

Required baseline exams:

• CT scan at L4-L5 or whole-body DEXA to quantify VAT. CT remains the reference standard used in registration trials. DEXA with CoreScan software offers lower radiation and reasonable correlation [6].
• Malignancy screening. The FDA label carries a precaution against use in patients with active malignancy because GH and IGF-1 are growth-promoting. A recent cancer history review and age-appropriate screenings (colonoscopy, PSA if applicable) should be documented [3].

IGF-1 Monitoring: The Most Important Recurring Lab

IGF-1 is the single lab that determines whether tesamorelin therapy continues or stops. There is no ambiguity in the label on this point.

The FDA prescribing information instructs clinicians to obtain IGF-1 levels "at baseline, within the first 4 to 6 weeks, and then every 6 months" [3]. Many HIV specialists tighten this to every 3 months during the first year, a practice supported by the observation that IGF-1 elevations tend to plateau between weeks 4 and 12 [7]. In the phase III data, mean IGF-1 increased by approximately 81 ng/mL above baseline in the tesamorelin group, with 5.4% of patients exceeding 3 times the upper limit of normal [1].

Decision thresholds:

• IGF-1 within age-adjusted range: continue therapy, recheck in 3 to 6 months.
• IGF-1 between 1x and 3x the upper limit of normal: continue with closer surveillance (every 8 to 12 weeks) and clinical judgment.
• IGF-1 persistently above 3x the upper limit of normal: discontinue tesamorelin per label guidance [3].

The word "persistently" matters. A single elevated value warrants a confirmatory repeat draw 4 weeks later. The Endocrine Society consensus on GH-related therapy notes that transient IGF-1 spikes can reflect assay timing, acute illness, or recent high-protein meals rather than true sustained overproduction [4].

Glucose and Metabolic Monitoring

GH antagonizes insulin action at the level of skeletal muscle and adipose tissue. Tesamorelin's stimulation of endogenous GH release carries a real, quantifiable risk of dysglycemia.

In the combined phase III dataset (N=816 across treatment and placebo arms), fasting glucose increased by a mean of 3.4 mg/dL in the tesamorelin group versus 0.2 mg/dL in the placebo group at 26 weeks [2]. HbA1c changes were small but statistically significant: +0.04% with tesamorelin versus -0.03% with placebo [3]. These population-level averages mask a tail of patients who developed clinically relevant glucose changes. Among patients with pre-existing impaired fasting glucose (100 to 125 mg/dL at baseline), 9% progressed to diabetes criteria during treatment [3].

Recommended glucose monitoring schedule:

• Fasting glucose and HbA1c at baseline.
• Fasting glucose at weeks 4 and 12.
• HbA1c at 3 months and 6 months.
• After the first year with stable values, HbA1c every 6 months is reasonable for most patients.

Patients already on antiretroviral regimens that affect glucose metabolism (older protease inhibitors, for example) require extra vigilance. The interaction is additive, not synergistic, but the combined burden can push borderline patients across diagnostic thresholds [8].

Lipid Panel and Cardiovascular Markers

Tesamorelin's effect on lipids is one of its more favorable pharmacologic properties, but it still requires monitoring to confirm that individual patients actually benefit.

In the 26-week phase III trial, tesamorelin reduced triglycerides by a mean of 50 mg/dL compared to placebo, with more pronounced effects in patients whose baseline triglycerides exceeded 200 mg/dL [1]. Total cholesterol and LDL showed smaller, inconsistent changes across studies. The non-HDL cholesterol to HDL ratio improved modestly [2]. A 2019 analysis by Fourman et al. at Massachusetts General Hospital examined tesamorelin's effects on coronary artery calcium progression in HIV-infected patients and found no significant acceleration over 12 months [9].

Lipid monitoring schedule:

• Fasting lipid panel at baseline.
• Repeat at 6 months to assess treatment effect.
• Annually thereafter if lipid values are stable and the patient remains on statin therapy as indicated.
• If triglycerides were the primary metabolic concern driving treatment, quarterly lipid panels for the first year provide better resolution.

Liver and Body Composition Assessments

The liver story is where tesamorelin monitoring has evolved most since initial approval. Tesamorelin was approved for visceral fat, not liver disease. But the GH-IGF-1 axis directly regulates hepatic lipid export via VLDL assembly, and data now suggest meaningful liver fat reductions in patients with HIV-associated NAFLD.

Stanley et al. (2014) conducted a randomized trial (N=61) showing tesamorelin reduced hepatic fat fraction by 37% at 12 months, measured by magnetic resonance spectroscopy, compared to a 10% increase in the placebo group [5]. ALT normalized in a significant proportion of treated patients. These findings prompted the AACE to include tesamorelin as a consideration for managing hepatic steatosis in HIV-positive patients, though this remains off-label [10].

Liver monitoring:

• ALT and AST at baseline, 3 months, and 6 months.
• If baseline hepatic steatosis is present, consider MRI-PDFF (proton density fat fraction) at baseline and 12 months to quantify response.
• GGT and alkaline phosphatase add limited value in routine monitoring but should be included if baseline values are abnormal.

Body composition imaging:

• CT at L4-L5 or DEXA at baseline and 6 months. The FDA label states that tesamorelin should be discontinued if visceral fat has not decreased after 6 months of treatment [3].
• Annual DEXA thereafter to track lean mass and bone mineral density. GH-axis stimulation tends to preserve or increase lean mass, and in the trial extension, patients on tesamorelin gained approximately 1.2 kg of lean body mass over 52 weeks [2].

Monitoring for Fluid Retention and Injection-Site Reactions

Tesamorelin's adverse effect profile is mild relative to exogenous GH, but two categories deserve systematic tracking during clinic visits.

Fluid retention occurs in approximately 5.5% of tesamorelin-treated patients versus 2.9% on placebo [3]. Symptoms include peripheral edema, joint stiffness, and carpal tunnel syndrome. These effects typically manifest in the first 8 weeks and may resolve spontaneously. Physical exam at each visit should include assessment of peripheral edema, grip strength complaints, and Tinel's sign if carpal tunnel symptoms are reported.

Injection-site reactions (erythema, pruritus, pain, hemorrhage) occurred in 8.5% of patients in the pooled safety analysis [3]. Most are self-limited. Document injection-site rotation at each visit and inspect for lipohypertrophy, which can alter drug absorption if the same site is used repeatedly.

Additional monitoring considerations:

• Thyroid function (TSH, free T4) at baseline. GH can increase T4-to-T3 conversion and unmask subclinical hypothyroidism. Repeat annually or if fatigue symptoms emerge [4].
• Complete blood count at baseline and 6 months. Not specifically required by the label but reasonable given the systemic effects of GH-axis activation.
• Serum cortisol is not routinely needed unless adrenal insufficiency is suspected, as tesamorelin does not significantly alter the HPA axis at approved doses [3].

Putting the Schedule Together: A Practical Timeline

The table below synthesizes label requirements with specialist practice patterns into a single monitoring timeline.

Pre-treatment: IGF-1, fasting glucose, HbA1c, fasting lipid panel, ALT/AST, TSH, CBC, CT or DEXA for VAT, malignancy screening.

Week 4 to 6: IGF-1 (first safety check), fasting glucose, assessment for fluid retention and injection-site reactions.

Month 3: IGF-1, HbA1c, ALT/AST, clinical assessment.

Month 6: IGF-1, HbA1c, fasting lipid panel, ALT/AST, CT or DEXA for VAT (treatment response decision point). If VAT has not decreased, consider discontinuation per FDA guidance [3].

Month 12: IGF-1, HbA1c, fasting lipid panel, ALT/AST, TSH, CBC, DEXA for lean mass and bone density.

Annually thereafter: IGF-1 every 6 months, HbA1c every 6 months, lipid panel annually, hepatic panel annually, DEXA annually, age-appropriate cancer screening.

Dr. Colleen Hadigan of the National Institutes of Health has stated: "Ongoing monitoring of IGF-1 and metabolic parameters is the foundation of safe long-term tesamorelin use in HIV-associated lipodystrophy" [7].

The most commonly missed lab in clinical practice is the 6-month VAT reassessment. Without it, patients may continue an expensive therapy (Egrifta SV costs approximately $1,000 to $1,500 per month before insurance) that is not producing measurable benefit [3].